Journal
SEMINARS IN IMMUNOLOGY
Volume 13, Issue 1, Pages 27-39Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1006/smim.2001.0293
Keywords
immunomodulation; MHC class I; MHC class II; varicella zoster virus
Categories
Funding
- NCI NIH HHS [CA94605] Funding Source: Medline
- NIAID NIH HHS [AI36884, AI20459] Funding Source: Medline
Ask authors/readers for more resources
Varicella zoster virus (VZV) is a human herpesvirus that causes varicella (chickenpox) during primary infection, establishes latency in dorsal root ganglia and may reactivate years later, producing herpes zoster. VZV must evade antiviral immunity during three important stages of viral pathogenesis, including the cell-associated viremia characteristic of primary infection, persistence in dorsal root ganglia during latency and the initial period of VZV reactivation. Our observations about the immunomodulatory effects of VZV document its capacity to interfere with adaptive immunity mediated by CD4 as well as CD8 T cells, ensuring the survival of the virus in the human population from generation to generation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available